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Objectives The aim of this study was to use positron emission
tomography (PET)-derived carbon (C)-11 acetate kinetics to de-
termine the effects of dobutanulne on oxidative metabolism and its
effects on myocardial efficiency in a group of patients with dilated
cardiotanyopathy .
Background. Dobutamine is known it) improve myocardial func-
tion but may do so at the expense of myocardial oxygen consumption,
which could be a potential deleterious effect . Carbon-11 acetate
kinetics correlate with myocardial oxygen consumption as shown in
animal models. Combining these scintigraphic measurements of
oxygen consumption with estimates of cardiac work results in a
work-metabolic index, which reflects cardiac efficiency .
Methods . Eight patients with nonischemic dilated cardiomyop-
athy underwent dynamic PET imaging, echocardiography and
hemodynamic measurements. Seven of these patients were also
studied while receiving dobutamine . Direct measurements of
myocardial oxygen consumption using coronary sinus catheteriza-
tion were obtained with eight of the PET studies to validate C-I1
acetate in patients with cardiomyopathy .
Results. The mean (:t SD) C-11 clearance rate significantly
incre ed with dobutamine from 0.105 ± 0.027 to 0.155 ±
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0.023 min - ' (p = 0 .001) ° Directly measnred myocardial oxygen
consumption had a linear relation to the mean C-11 clearance rate
(r = 0.8, p = 0 .018). Dobutamite was noted to significantly
reduce systemic vascular resistance as well as the severity of mitral
regurgotation° The work-metabolic index determined using
11e1rio-
dynamic variables and PET data increased from 2 ± 0 .7 x 1W to
2.6 ± 0.6 x 104 (p = 0.04) . Efficiency, estimated by employing the
oxygen consumption to k2 relation, also increased from 13 ± 4 .5%
to 16.9 ± 6.4% (p = 0.04) .
Conclusions . Despite an increase in myocardial oxygen con-
sumption, dobutauine led to an increase in work-metabolic index
in patients with dilated nonischennic cardiomyopathy . bu 9
reduced systemic vascular resistance and mitral regurgitation, sug-
gesting that in this group of patients, it had important vasodilator)
action in addition to its inotropic effects . The ntce of the C-I l acetate
PET for determining myocardial oxygen consumption and esti t-
itg efficiency could potentially complement existing c ` ical measures
of ventricular performance and may allow improved and objective
evaluation of therapy in patients with heart failure.
(J Am Coll Curdiel 1993,22 :1389-98)
Dobutamine, a synthetic sympathomimetic amine modified
from isoproterenol (1), is commonly used as intravenous ther-
apy for congestive heart failure . This drug has been shown to
significantly improve cardiac performance and hemodynamics
and to lessen symptoms in such patients (2-8) . These improve-
ments seen with dobutamine may be sustained over prolonged
periods of time (3,4) . However, treatment with inotropic agents
may be detrimental, adversely affecting long-term outcome in
certain cases (9-12) . One proposed mechanists for these po-
tentially deleterious effects of inotropic agents is that improved
performance occurs at the expense of increased oxygen con-
sumption (10.12) .
Recently, the myocardial kinetics of radiolabeled ace alu,
which can be determined noninvasively using positron emis-
sion tomography (PET) have been used to measure rates of
oxidative metabolism in the heart (13-21) . A direct relation
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between carbon (C)-II acetate turnover kinetics and mea-
sures of myocardial oxygen consumption has been demon-
strated in both animal studies (13,14) and normal human
subjects (16,17) . This relation has also been applied in our
laboratory to determine myocardial efficiency in experimen-
tal heart failure (22) and determine a work-metabolic index
as an estimate of efficiency in patients with dilated cardio-
myopathy (21). This latter study and other clinical investi-
gations (15,20) assume that the C-11 acetate kinetics-
myocardial oxygen consumption relation can be applied in
patients with impaired ventricular function . However, this
has not been established .
The aim of this study was to determine the effects of
dobutamine on PET-derived C-1 I acetate kinetics as a measure
of oxidative metabolism and its effects on a work-metabolic
index in a group of patients with dilated cardiomyopathy . In
addition, C-11 acetate kinetics were compared with directly
measured oxygen consumption from a subset of this group of
patients . The relation between these two measurements was
used to determine the effects of dobutamine on myocardial
oxygen consumption and cardiac efficiency .
b4oleds
The study protocol was reviewed and approved by the
Human Subjects committee at the University of Michigan
Medical Center on August 15, 1991 and the Radiation Safety
Committee at the University of Michigan Medical Center on
October 15, 1990 . Informed consent was a prerequisite for
inclusior in the study .
Patient Selection
Eight consecutive patients with dilated cardiomyopathy
were enrolled in the study . Patients were included if they had
impaired left ventricular function with an ejection fraction
<30%. Patients were excluded if they had any of the following :
1) evidence of myocardial infarction by history or by electry
cardkInwa (E00G); 2) angiographic evidence for a coronary
artery stenosis of >50% diameter; 3) valvular stenosis; 4)
Primary valvular insufficiency; 5) unstable ventricular arrhyth-
HEMODYNAMIC MONITORING
DOBUTAMINE INFUSION
CORONARY SINUS FLOW AND OXYGEN CONSUMPTION MEASUREMENTS
Figure 1 . Experimental protocol . C carbon ;
ECHO = echocardiography; PET positron
emission tomography.
mias, or 5) pregnancy. The baseline hemodynamic and
echocardiographic data from one patient have been previously
presented (21) but are included in this study because the patient
also had direct myocardial oxygen consumption measurements
that have not been previously Deported .
Experimental Protocol
The protocol is outlined in Figure 1 . Each patient had a
pulmonary artery catheter inserted for clinical indications,
which remained in place for the duration of the study . The
protocol consisted of two phases : evaluation at baseline and
during dobutamine infusion . Each phase included a C- I I
acetate PET study and a two-dimensional echocardiogram .
All patients completed the baseline phase . Seven patients
received dobutamine infusion for a total of 15 PET and
echocardiographic studies (8 baseline and 7 dobutamine) . Of
these 15 studies, 8 included direct measurement of myocar-
dial oxygen consumption by means of the coronary sinus
catheter (5 baseline and 3 dobutamine) . All studies were
performed on the same day. All patients fasted overnight and
received no oral medication for a12 h before the study .
Baseline studies. Hemodynamic measurements. The ECG
was monitored continuously. An arterial line was inserted in
the radial artery and used for arterial pressure monitoring and
arterial oxygen sampling, except in one subject with difficult
radial artery access . In the latter patient, a noninvasive blood
pressure cuff was used for recording blood pressure every
5 min during baseline study and every 2 min during the
dobutamine phase. Standard hemodynamic measurements,
including pulmonary artery pressure, right atrial pressure,
pulmonary capillary wedge pressure and cardiac output, were
made during the PET study . Mean data were calculated from at
least two complete sets of hemodynamic measurements taken
during each acquisition .
Coronary sinus blood flow and oxygen consumption
measurements . In five subjects after right heart catheteriza-
tion, a dual-port/triple-thermistor Baint coronary sinus flow
catheter (Electro-catheter Corporation) (23) was advanced
into the coronary sinus through a second puncture of the
right internal jugular vein . The position of the distal port
QVI ACETATE
20 mCI
C-11 ACETATE
20 mCI
I
DYNAMIC
DYNAMIC
i
ECHO PET
I
I PET
i
ECHO
I
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(catheter tip) of the catheter was confirmed to be in the
coronary sinus by contrast medium injection . Coronary
venous samples from the catheter tip and radial artery
samples were drawn for oxygen content . The catheter was
interfaced with a Baim coronary sinus flow analyzer and
calculator (Electro-catheter Corporation) and this system
connected to a strip recorder (Marquette model 4033) . Cor-
onary venous flow was measured from the distal thermistor
using the thermodilution technique of Ganz et al . (24) . The
thermal indicator was a 5% dextrose in water solution at
room temperature delivered at 43 ml/min using a Harvard
infusion pump. The mean of at least two to three measure-
ments made in the catheterization and PET laboratory were
used for data analysis . These measurements were alternated
with thermodilution cardiac output determinations . In one
patient, the catheter was removed before the PET scan ; in
another, there was a significant change in the coronary
venous oxygen content and flow at the time of the PET scan
despite stable hemodynamic status, suggesting that the cath-
eter was no longer in the coronary sinus . In these patients,
data from the catheterization laboratory were used to calcu-
late the baseline measurements . On one occasion, flow
measurements from the distal thermistor were very low
(25 ml/min per 100 g) because the catheter tip was well into
the great cardiac vein . In this case, the proximal catheter
thermistor data were used .
Echocardiography. Before the PET study, a two-
dimensional echocardiogram was performed . This was after
the catheterization in five patients and immediately before
catheterization in three . Apical two and apical four chamber
views as well as parasternal short- and long-axis views were
recorded on videotape for subsequent analysis . Subsequent
analysis was undertaken by a single experienced observer
who had no knowledge of the clinical and hemodynamic
patient data
. All quantification was performed on a commer-
cially available microprocessor-based off-line analysis sys-
tem (Prism Imaging, Freeland Medical Systems) . All mea-
surements were made in triplicate and the average of all
three measurements was used for analysis .
Positron emission tomography . After the baseline
echocardiogram, the patient was positioned in a 931 Siemens
PET scanner (Hoffman Estates, IL), which has eight circular
detector rings, allowing the acquisition of 15 contiguous
transaxial images with a slice thickness of 6 .75 mm. A
20-min transmission scan was performed and the data were
used to correct the emission images for photon attenuation .
Twenty millicuries (740 MBq) of C-11 acetate, synthesized
using the technique described by Pike et al . (25), was then
administered intravenously over 30 s . A 30-min dynamic
frame acquisition was simultaneously initiated (10 x 10 s,
I x 60 s, 5 x 100 s, 3 x 180 s, 2 x 300 s).
Dobutamine studies. After the baseline acquisition was
completed, an infusion of dobutamine was initiated at
5 pg/kg per min in seven patients . The infusion was in-
creased by 5 pg/kg per min every 5 min to increase the
cardiac output by 50% provided that systolic blood pressure
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had not decreased by >20 or >40 mm Hg and the heart rate
had not increased to greater than 140 beats/min
. The infusion
was reduced if symptoms developed or if there was an
increase in ventricular ectopic activity . Once a stable infu-
sion rate was achieved (mean dose 13 .2 ± 9 .2 pgikg per
min), it was maintained for 15 min before a second 20-mCi
injection of C- I I acetate was administered intravenously .
This was followed by the same dynamic positron emission
tomographic acquisition described for the baseline study
. At
the completion of this acquisition, the patient was removed
from the positron emission tomographic scanner and the
echocardiogram was repeated while the dobutamine infusion
was maintained . Hemodynamic measurements were also
recorded during the dobutamine studies. Coronary sinus
flow and arterial-venous blood sampling were completed in
three subjects . After the completion of the echocardiogram,
the dobutamine was titrated down and the pulmonary artery
and coronary sinus catheters were removed .
Data Analysis
Hek'fi6dynawics . The stroke volume (SV) was calculated
from cardiac output divided by heart rate . Left ventricular
stroke work index (LVSWI) was determined from the fol-
lowing equation (26,27) :
SV x (MAP - PCWP) x 0.0136
LVSWI =	BSA
	 - Ig-m/flill, [I]
where MAP is the mean arterial pressure, PCWP is pulmo-
nary capillary wedge pressure and BSA is the body surface
area. The number 0 .0136 represents a constant with units
p-m/ml per mm Hg .
Systemic vascular resistance (SVR) was estimated using
the following standard equation (27) :
SVR = (MAP - RAP) X 80
CO
	 [dynes-s/cmll, [2)
where RAP is right atrial pressure, CO is cardiac output and
the number 80 is a constant with units titers-dynes/rm5 per
mm Hg .
Echocardiography. Left ventricular volumes were deter-
mined using a modified Simpson rule (28,29) and the stroke
volume calculated from the difference between end-diastolic
volume and end-systolic volum . The left ventricular mass
was determined using the assumption of an inner and outer
ellipse, with the thickness between them defined as the mean
left ventricular wall thickness measured on the parasternal
short-axis view (29,30) .
The stroke-volume index (SVI) determined by echocar-
diography was used to estimate stroke work (SWIG) with the
following equation :
SWI, ~ SVI X PSP, 131
where PSP represents the peak systolic blood pressure
.
Circumferential wall stress (CWS) was calculated accord-
ing to the following equation :
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CWS = 1.33 x PSP X (1 -
4Ae?
[4]
	 VA,
At - Ac
A
where AC is the short-axis area bordered by the endocar-
dium, A, is the short-axis area bordered by the epicardium
and L is the long-axis of the ventricle .
Mitral regurgitation, identified using Doppler echocardi-
ography, was graded visually for each study on a separate
occasion without knowledge of hemodynamic or PET data
or prior echocardiographic measurements . The scoring sys-
tem was 0 = no or trivial regurgitation ; I = mild; 2 =
moderate and 3 = severe regurgitation (31).
Positron emission tomograpllic data processing. The
reconstructed transaxial images were reoriented along the
long-axis of the left ventricle to yield resliced images along
the horizontal-, vertical- and short-axis of the heart using a
Sun 4 Workstation (Sun Microsystems Inc.) and software
developed at the University of Michigan (18), The reoriented
short-axis i es served as input data to a semiautomated
regional analysis program also developed at our institution .
In a. midventricular short-axis plane, the temporal image
where myocardial activity was highest (usually the 11th or
12th frame) was used to define inner and outer ellipses
placed on the boundaries of the left ventricle . In the same
plane, a 3 x 3 pixel region of aaterest was defined over the
left ventricular blood pooi . These regions were applied to all
the images in the dynamic sequence for that plane and
myocardial sector and blood pool time-activity curves de-
rived .
Carbon-11 acetate tics. A two-compartment model
was then fit to the time-activity data, This model accounts
for the recirculation of C-11 acetate by determining the
arterial input function corrected for C-I1 metabolites, prin-
cipally C-I1 carbon dioxide in the blood. This approach has
been validated in animals and humans by our laboratory and
is described in detail elsewhere (30) . The model solves for
five variables : the K 1 and k2 rate constants between the
vascular and tissue compartments (k 2 being the C-11 clear-
ance from tissue) ; a correction for the vascular space in the
sampled myocardial region; a variable representing the ap-
pearance half-time of C-11 carbon dioxide in the blood (gm) ;
and a variable that defines the fraction of total C-1I blood
concentration that is C-11 carbon dioxide at the end of the
acquisition (a0) .
Work- index. The scintigraphic C-I1 clearance
data were combined with the stroke-work data (equation 1)
to determine the left ventricular work metabolic index as
described previously (21). Using the invasive hemodynamic
data, the equation for work-metabolic index (WMI h) was as
follows :
WMIh =
HR x LVSWIh
z
k2
The work-metabolic index was also determined using the
echocardiographic data (WMIj as follows:
(5]
SVI x PSP x HR
(mm Hg-ml/m)
.
[61WMIe =
k
2
The units for work-metabolic index were arbitrary in both
equations 5 and 6. These equations for the work-metabolic
index are modifications of the equation for left ventricular
mechanical efficiency described by Bing et al . (32) and others
(7-9,33-38). The denominator in these other studies was
measured oxygen consumption, which has been substituted
by k2 in these two equations .
Measurement of myocardial oxygen consumption . Myo-
cardial oxygen consumption (MVD2 ) was determined with-
out correction for mass by the equation :
OF X (ACSBO,)
Total MVO, -
itt0
- - ( ml 02/min) [7a]
and with correction for mass by the equation :
CBF x (ACSOO,)
Total MVO, _ ® LVM (ml O,/rain per 100 g), (7b]
where CBF is coronary sinus flow (ml/min), ACSD0 2 is the
arterial to coronary sinus oxygen content difference [vol%]
and LVM is left ventricular mass (g) determined from the
corresponding echocardiogram for each oxygen consump-
tion measurement (five at baseline study, three during the
dobutamine study) . The measurement of flow per unit mass
is an approximation that assumes that the measured coro-
nary sinus flow reflects venous return from most of the left
ventricle .
Myocardial oxygen extraction was expressed as the ratio
of the arterial to coronary sinus oxygen content difference to
the arterial oxygen content (33) .
Estimation of myocardial oxygen consumption from
carbon-11 acetate kinetics . Myocardial oxygen consump-
tion was plotted against k2 and the line of regression used to
estimate myocardial oxygen consumption from the C-II
acetate kinetic data. In this case, because myocardial oxy-
gen consumption was the unknown to be solved, it was
plotted on the y axis . Because k2 is independent of mass,
myocardial oxygen consumption corrected for mass (equa-
tion 7b) was used to establish the relation .
Myocardial efficiency . Myocardial efficiency was deter-
mined from the following standard, well established formula
(7,8,32,34,35) :
LVSW x HR x 100
Efficiency = -- (%), [8]
Total MVO2 x c
where LVSW is left ventricular stroke work determined hemo-
dynamically and c is a conversion factor representing the
energy equivalent per ml of oxygen metabolized, equal to
2,059 gm/ml oxygen consumed . Because efficiency was calcu-
lated from derived values of myocardial oxygen consumption
corrected for mass expressed in ml/min per 100 g, left ventric-
ular stroke work was also corrected for left ventricular mass .
JACC Vol . 22, No . 5
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Table 1 . Patient Clinical Chararleristics
patient a incr
;
ent case v,a ectopic activityar
that occurred during the dobutamine titration, resolved with
use of a lower dose
. During dobutamine titration, one patient
experienced atypical chest discomfort that resolved at a
lower dose
. One patient (Case 6) experienced vomiting
15 min into the PET image acquisition . The dobutamine dose
was decreased by 5 ag/kg per min and was tolerated well .
With this dose reduction, the hemodynamic variables
changed by :515% for the remainder of the acquisition
. A
mean of two sets of measurements before and two after the
dose change were used to calculate the hemodynamic data
for this patient's study .
Study intervals . The mean time between the start of the
baseline echocardiogram and the baseline C-11 acetate in-
jection was 141 ± 112 min . The mean time between the
second C-11 acetate injection and the second echocardio-
graphic study was 43 ± 11 min . The mean time between the
Statistical analysis . All measurements were expressed as coronary sinus catheterization and baseline C-11 acetate
mean value ± I SD. Baseline measurements were compared injection was 106 ± 38 min .
with dobutamine measurements by paired Student
1 testing, Hemodynamic data. The hemodynamic data are summa-
with p
g
0.05 considered significant . Myocardial oxygen rized in Table 2 . Dobutamine significantly increased heart
consumption was compared with C- I I clearance (k 2 ) by rate, cardiac index, stroke-volume index and stroke-work
regression analysis . index (p ~ 0 .01) but did not significantly affect mean arterial
pressure . Systemic vascular resistance decreased signifi-
cantly (p = 0 .002) . Pulnsonary capillary wedge pressure also
decreased, but the reduction was not statistically significant .
Patient characteristics. The characteristics of the eight Echocardiographic data . Heart rate, peak systolic pres-
patients in this study are noted in Table 1 . One patient (Case sure, volume measurements and circumferential wall stress
8) had increased diastolic blood pressure and was not studied at the time of each echocardiographic study are summarized
with dobutamine . All patients were receiving a loop diuretic in Table 3. End-systolic volume index and end-diastolic
agent and digoxin, seven were taking an angiotensin- volume index decreased with dobutamine, but these changes
converting enzyme inhibitor and two were taking nitrates . did not reach statistical significance . However, calculated
Two patients with a history of ventricular arrhythmias were stroke-volume index and ejection fraction did increase sig-
in stable condition with treatment by antiarrhythmic agents : nificantly (p < 0 .005) . Mean circumferential wall stress did
amiodarone in one and metoprolol in the other . In the latter not change during dobutamine infusion .
F = female ; LVEF = left ventricular ejection fraction from baseline
echoardiographic study ; M = male ; NYHA = New York Heart Association ;
Pt - patient .
Results
Table 2
. Hemodynamic Daina k2 and WOrK -Metabolic Index During Baseline and Dobutamine Positron Emission Tomographic Studies
1393
Mean values ± SD are reported for Patients I to 7
; p values apply to paired comparisons between baseline positron emission tomographic study (0) and
dobutamine positron emission tomographic study (D) for each variable
. C-11 = carbon-11
; CI = cardiac index ; HR = heart rate
; k2 = C-11 clearance rate
;
LVSWI = left ventricular stroke-work index ; MAP = mean arterial pressure
; PCWP = pulmonary capillary wedge pressure
; Pt = patient
; SVI = stroke-volume
index ; SVR = systemic vascular resistance
; WMIh = work-metabolic index calculated using hemodynamic data (equation 5)
.
Pt NYHA
No . Age (yr)lGender
Class LVEF
I 351M 4
0.19
2
32/M 3 0.19
3
55/F
3 0.22
4 40/F
3 0.26
S
50 3 0 .20
6
OF 3 0 .23
7 431M
2 0 .27
8 49/M 2
0 .17
Mean 45 2 .9
0 .22
±SD 9 0.6 0 .04
No. B '3 B D
B D B D B D B D B D B D
B D
1 101 132 100 86 36
20 2 .7 4 .9 27 37 1 .102 521 23 33
0 .108 0.154 2.2 2 .8
2 102 116
9U 86 27 22 1 .6 4 .5 16 39
1,858 680 13 34 0 .103 0.137 1 .3
2 .5
3 82 106 90 99 10 10 2 .5 4 .3 31
41
1,339
847 33 49
0 .140 0.177 2 .0 2 .9
4 106 104 89 91 24 18 2 .8
4 .3 26 41 1,185 776 23 41
0 .089 0.133 2 .8 3 .2
5 87 125
96
99 12 12 1 .8
3 .1
21
25 1,777 1,122 24 30
0 .142 0.190 1 .5
2 .0
6 54 73 65
77 21 19 1 .5 2 .6 27 36 1,597
1 .115 16 28 0 .073 0,127
1 .2 1 .6
7 66 100 83 93 17 16 2 .7 4 .1 42 41
1,288 982 37 43
0 .080 0.150 3 .1 2 .8
8 87 107 12 3 .0 34
1,464
44 0 .101 3 .8
Mean 85 108 87 90 21 16 2 .2 4 .0
27 37 1,449 863 24 37
0 .105 0.155
2
.0 2
.6
tSD 20 19 11 8
9
4 0 .6 0 .8
8 6 296 225
9 8 0 .027
0.023 0.7 0 .6
P value 0.005
0.50 0 .08 0 .0003 0 .01 0 .002
0 .001
0.0001
0.04
HR MAP PCWP
CI
(liters/min SVI
SVR LVSWI k 2
WMI,
(beats/mint (mm Hg) (mm Hg) per a,'-)
(ml/M2)
(dynes
. S/Cm 5 )
(g . m1m3) (min -1 ) (x 1W)
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TaW 3
. Echocardiographic Data and Work-Metabolic Index During Baseline and
Dobutamine Echocardiographic Studies
Pt
No .
HR
(beats/min)
B D
PSP
(mm Hg)
B
D
EDVI
(ml/m2)
B D
ESVI
(ml/ml)
B
D
More than trivial mitral regurgitation was present in six
patients at baseline . However, with dobutamine, all patients
had absent or trivial mitral regurgitation . This change was
statistically significant (p® 0.005).
Calle*41 acetate Ithledes . An example of dynamic C -I I
acetate PET acquisition is shown in Figure 2 at baseline and
during dobutamine . Note the sequence of activity : in the
early frames (frames I to 10 were 10-s acquisitions), C- I I
appears rapidly in the right ventricular chamber, followed by
the left ventricular chamber, then gradually the myocardium
becomes defined, In the later images (frames 16 to 21 were 3-
and 5-min acquisitions), myocardium is less well defined,
SVI
(mum')
B D B
EF
D
CWS wxil~
MR Grade (kDfcm 2 ) (X101 )
B D B DB D
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Mean values ± SD are reported for Patients I to 7; p values apply to paired comparisons between baseline positron emission tomographic study (B) and
dobutmine positron emission tomographic study 0 for each variable, CWS - ci(cumfefetitial wall stress ; EDVI ~
end-diastolic
volume index ; EF = ejection
ftxtw. ESVI -
end-Systolic
volume index, MR - mitral regurgitation ; PSP - peak systolic pressure ; WMI, = work-metabolic index calculated using
echucardi file data (equation 6) ; other abbreviations as in Table 2,
representing clearance of C- I I as carbon dioxide . In this
example, the dobutamine study showed more rapid myocar-
dial C- I I clearance consistent with an increased C- I I clear-
ance rate and increased myocardial oxygen consumption .
The mean G I I clearance rate (k2) was significantly
increased with dobutamine from 0 .105 ± 0 .027 to 0.155 ±
0.023 min - ' (p = 0 .0001) (Table 2). The wide range of k,
values noted reflects the variation in baseline myocardial
oxygen consumption and hemodynamics in this group of
patients.
When directly measured myocardial oxygen consumption
(mlimin per 100 g) (Table 4) was compared with k
2
, a linear
Figure 2 . Example of a 21-frame dynamic positron
emission tomographic acquisition with varying
frame duration (10 x 10 s, 1 x 60 s, 5 x 100 s, 3 x
180 s, 2 X 300 s) at baseline (upper panel) and
during dobutamine (lower panel). The tracer ap-
pears first in the right ventricular chamber, then in
the left ventricular chamber. The myocardium then
becomes defined but is cleared in the later images .
1 103 131 133 127 188 172
153 135 35 37 0 .19 0.21 2 0 428 381 4.5 4 .0
2 103
118 118 151
146 121 118 90 28 32 0.19
0.26 3 0 381 499 3 .2 3 .6
3 82 107 115 123
95 77 75
56 20 21 0.22 0.27 1 0 397 352 1 .4 1 .6
4
109 104 129 152 129
123 95 90 34 33 0.26 0.27 2 0 421 359 4 .7 3 .9
5 87 129 128 129
104 116 83 21 27 0 .20 0.24
0
0 533
467
1 .5
2.4
6 56
63
105 125
81
74
63
53 18 21 0.23
0.29
2 0 298 329 0.6 1 .1
7 60 86 105 130 116
126 85 86 31 40 0.17 0.32 1 0 434 450 2 .5 3 .0
9 82 136
176 146 30 0,17 0 492 3 .3
men 86 105 119 134 123 116 96 85 27 30 0,22 127 1 .4 0.0 413
405 16 2 .8
AD 21 24 11 12 36 33 .40 27
7 7 0 .03 0.04 0 .9
0 .0
70 66 1 .6 1 .1
p value 0 .01 0,033
0 22 0.06 0 .04 0.002 0.005 0.77 0.42
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Figure 3 . Myocardial oxygen consumption versus C-11 acetate
clearance Q. The regression equation for this relation was used to
estimate myocardial oxygen consumption in the remaining seven
studies, which did not have direct oxygen consumption measure-
[news.
relation with a correlation coefficient of r = 0 .80 (p = 0 .018)
was noted (Fig . 3) .
Work-metabolic index. Data for the work-metabolic in-
dex are shown in Tables 2 and 3 . Dobutamine increased the
work-metabolic index from 2 ± 0.7 x
104
to 2.6 ± 0.6 x 10'
(p = 0.04) determined from hemodynamic data . In contrast,
the work-metabolic index calculated based on echocardio-
graphic variables did not change significantly from 2 .6
1 .6x
106
to 2 .8 ± 1 .1 x 106 (p = N S) .
Measurement of
myocardial efficiency. Myocardial effi-
ciency was estimated using equation 8 with the myocardial
oxygen consumption data derived from 14 . The estimated
myocardial oxygen consumption increased from 7 .9 ± 2
.2 to
11 .8 ± 1 .8 ml oxygen/min per 100 g (p = 0 .0001) with
dobutamine. The myocardial efficiency was also found to
increase significantly with dobutamine from 13 ± 4 .5% to
16.9 ± 6.4% (p = 0 .04) (Table 5) .
Table 4. Coronary Sinus Catheter Data During Baseline and Dobutamine Studies
02 = oxygen ; other abbreviations as in Table 2 .
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Table 5
. Myocardial Efficiency*
'Myocardial efficiency determined from equation 8, using hemodynamic
data for stroke work and myocardial oxygen consumption derived from the
relation to k 2 . t p = 0
.04 dobutamine vs baseline .
Discussion
These data demonstrate that despite an increase in myo-
cardial oxygen consumption, dobutamine increased myocar-
dial efficiency in patients with nonischemic dilated cardio-
myopathy . Efficiency was calculated from hemodynamically
determined stroke work corrected for myocardial oxygen
consumption, which was derived from a linear relation to
C- I I acetate clearance kinetics . The work-metabolic index
also improved when measured using hemodynamically de-
termined variables, but not when employing echocardio-
graphic data. Dobutamine also significantly reduced sys-
temic vascular resistance and mitral regurgitation,
suggesting that the observed efficiency response may be
related in part to vasodilator effects of the drug
.
Myocardial oxygen consumption determination with
carbon-11 acetate kinetics. In animal studies, PET-derived
C-1 I acetate turnover kinetics have been well correlated
with direct measures of oxygen consumption (13,14,19,22)
and indirect variables in normal human subjects (16,17,19).
The model approach to derive the clearance rate (k 2 ) has also
been correlated with indirect variables in patients with
normal left ventricular function
. The present study, how-
Patient
No .
Baseline
(%)
Dobutamine
1%I
1 9,3
Q7
9 .1 17 .3
3 19 .5
29 .9
4 16 .0 18 .7
5 10 .9 13 .4
6
8 .8 10 .8
7 17 .5 15 .7
8 17 .3
Mean 13 .0 16 .9'
±SD ±15
±64
Pt
Coronary Sinus Flow
Arteriovenous
0, Difference Myocardial 0 2
Extraction (%)
Myocardial 0 2 Consumption
(ml/min) (ml/min per g) (ml/mini (milmin per 100 g)(ml/100 ml)
B D B 1) B D B D
B DNo . B D
1 120 0.35 16.9 87 20
.2 5 .9
2 159 234 0.87 1 .31 12 .0 10.4 87
77 19 .1 24 .3 10 .4 13 .0
3 136 158 1 .06 1 .27 11 .6 10.7 75 68 15 .8
16 .7 12 .3 13 .5
7 104 153 0.51 0.76 10.5 10.8
59 61 11 .9 16 .4
5 .4 8X/
8 144 0.54 13 .6 71
19.6 7 .3
Mean 132 181 0.67 1 .11 12 .9 10.6 75
69 17.1 19 .2 8,3 11 .8
±SD ±21 ±45 ±0.29 ±0 .31 ±2 .5 ±0.2 ±11 ±8 ±3 .9
±4 .4 ±3 .0 *3 .1
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ever, is the first to our knowledge to document this relation
in patients with dilated cardiomyopathy (Fig. 3) and it
supports the linear relation between C-11 acetate turnover
kinetics and oxygen consumption observed in animal studies
(13-15,19,22) .
Measurement of efficiency . Two general approaches have
been used to measure the efficiency of energy transduction
from oxygen consumption into work. These are based on the
different measurements of work employed : either 1) the total
mechanical work, or 2) the external stroke work . The total
mechanical work of the ventricle represents the energy used
for excitation-contraction coupling and is the sum of the
potential energy and the external stroke work (38,39) . This
approach requires sophisticated invasive instrumentation to
acquire pressure-volume loops at various ventricular vol-
umes to derive a pressure-volume area, a measure of total
mechanical work (38,39) . However, routine clinical applica-
tion has been impractical, limited by the invasive nature of
the technique and because zero pressure-volume area cannot
be achieved in patient studies, so it must be extrapolated
from a small number of points (38) .
The determination of mechanical efficiency (external
work corrected for total myocardial oxygen consumption)
has been a more conventional approach (7,32-38) . External
work represents the useful portion of total mechanical work
that is realized by the body in terms of stroke volume and
systemic perfusion pressure. Both external stroke work and
mechanical efficiency are influenced by loading conditions
and inotropic state (40,41). However, the measurement of
mechanical efficiency does offer an advantage over standard
measures of ventricular performance by accounting for the
differing effects of load and contractility on oxygen con-
sumption and may thus have potential clinical utility . With
the proposed use of C-I1 acetate kinetics as a noninvasive
estimate of myocardial oxygen consumption, mechanical
efficiency can be more easily determined .
t of u on co ption
y. The effects of dobutamine on myocardial
oxygen consumption and efficiency have been previously
investigated (5,7,8) . Monrad et al. (7) showed that dobu-
tamine at 10 ± 3 per min increased myocardial
efficiency by 41 ± 41% of baseline in a mixed group of
patients with ischemic and nonischemic cardiomyopathy .
Mean myocardial oxygen consumption increased signifi-
cantly from 8.7 ± 2.1 to 11 .1 ± 3.8 ml oxygen/min . Kramer
et al . (5), using measurements of the pressure-volume rela-
tion, also demonstrated increased myocardial efficiency and
oxygen consumption in patients with dilated cardiomyopa-
thy by 25% and 14%, respectively . In contrast, a group of
patients with nonischemic cardiomyopathy and severely
impaired ventricular function studied by Sundram et al . (8)
had no increase in myocardial oxygen consumption with
15 pgAg per min of dobutamine, but had a significant
increase in efficiency from 9.5 ± 5% to 21 .7 ± 13% . In the
present study, there also was a significant change in efficien-
cy, with
a mean increase of 33 ± 32% of the baseline value,
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which is within the wide range of the previous reports . This
wide variation in the degree of response to dobutamine may
be related to patient differences in baseline hemodynamics
and oxygen consumption status .
Some investigators (8,9) have proposed that improved
efficiency with dobutamine in patients with severe heart
failure is related to its inotropic effect . They hypothesize that
improvement in contractile function leading to a decrease in
ventricle size would reduce wall stress . The latter would
reduce oxygen consumption and counterbalance the effect of
increased contractility . Alternatively, others (2,4) have sug-
gested that there may also be a primary vasodilator effect of
dobutamine that acts to reduce afterload . The present study
supports this latter hypothesis, given the small changes in
ventricular size but marked reduction in systemic vascular
resistance. Reduced vascular resistance has been reported
by others (2,5®7) . Although it is possible that some of this
change in vascular resistance is a reflex response to in-
creased forward output (2), we (42) also observed a marked
reduction in mitral regurgitation that is more typically ob-
served with primary vasodilator agents. In addition, Liang et
al. (4) measured norepinephrine levels after dobutamine
infusion and found that they did change, suggesting that this
was not a reflex phenomenon. Also, dobutamine is known to
be a mild beta2-agonist (1) and its (+)-isomer has been shown
to have alpha-receptor blocking effects (43), both of which
could contribute to a primary vasodilation effect .
It is of interest that despite the reduction in vascular
resistance, there was no change in the mean circumferential
wall stress . The latter may be a more accurate reflection of
ventricular afterload (6) . On close examination of the data,
however, wall stress did decrease in four patients, whereas
in two other patients (Cases 2 and 6), it increased markedly .
These two patients had the lowest baseline wall stress and
had significant lnitral regurgitation that almost completely
resolved with dobutamine. At baseline, the mitral regurgita-
tion would reduce wall stress, but conversion of regurgitant
volume to forward stroke volume would tend to increase it .
The lessening of mitral regurgitation also accounts for the
discrepancy between the hemodynamic and echocardio-
graphy-derived work-metabolic index due to the different
methods for calculating stroke volume . In all four patients
with a mitral regurgitation grade >_2, there was a markedly
lower absolute change in stroke volume by echocardiogra-
phy than by thermodiyution . Thus, in the presence of mitral
regurgitation, the two work-metabolic index measurements
yield complementary data . The hemodynamic work-
metabolic index reflects forward efficiency or the energy
transduction into forward stroke work, whereas the
echocardiography-derived measurements reflect the overall
stroke work and efficiency. In general, previous reports on
the effects of dobutamine on stroke work and mechanical
efficiency have utilized hemodynamic equations (equation 8)
and have not recognized this potential for improvement in
mitral regurgitation .
JACC Vol . 22, No . 5
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Technical considerations and limitations. Heinodynamic
variability. One limitation of this protocol was that echo-
cardiographic and PET data were not measured simulta-
neously . As a result, small variations in loading conditions
and contractile state between data acquisitions are inevita-
ble. These were kept to a minimum in this study by having
the studies performed as close in time to one another as
possible and by careful monitoring of the patients' hemody-
namic status .
Measurement of myocardial oxygen consumption. In
this study, myocardial oxygen consumption was directly
measured using coronary sinus catheter measurements and
also estimated from the relation of oxygen consumption to
k2. In published studies, there is a wide variation of values
for myocardial oxygen consumption in patients with cardio-
myopathy and impaired ventricular function (7,8,33-37),
ranging from a mean of 7.6 ml oxygen/min (34) to a mean of
24.5 ml oxygen/min (37) . The values in the present study are
within this range . The mean myocardial oxygen consump-
tion corrected for left ventricular mass is also in the range
reported by Baxley et al . (35) (6 .2 to 14.5 ml/min per 100 g
and Bing et al . (32) (7 .2 to 10 .4 ml/min per 100 g) . This wide
variation reflects the wide range of coronary flow measure-
ments in these studies, from a mean of 67 mUmin (34) to a
mean of 195 ml/min (36) without considering mass and from
0.48 to 0 .97 ml/min per g with mass correction (35) . Such
variability is probably due in part to the different methods
used for measuring global coronary flow, different positions
of the coronary sinus catheter in the coronary sinus and the
variability of coronary venous return such that measured
flow does not reflect the entire left ventricle or includes flow
from other cardiac structures . However, the measurement of
oxygen extraction, which does not depend on the measure-
ment of flow for its calculation, is much more consistent in
reports (7,32-34,36,37), ranging from a mean of
11 .1 ml/100 ml (34) to a mean of 15 .1 ml/100 ml (37), which is
consistent with our results (Table 4) .
Sample size . Although the sample size was small, it was
sufficient to demonstrate significant changes in C- I I acetate
kinetics, the hemodynamic work-metabolic index and effi-
ciency and mitral regurgitation with dobutamine as well as
the myocardial oxygen consumption-k2 relation . Large scale
clinical trials are necessary to establish the utility of this
approach in optimizing ventricular performance and clinical
outcome .
Conclusions. In a group of patients with dilated cardio-
myopathy, dobutamine increased the myocardial C- I I clear-
ance rate from C- I I acetate consistent with an increase in
myocardial oxygen consumption and concomitantly in-
creased the work-metabolic index measured by hemody-
namic variables . Myocardial oxygen consumption estimated
from its relation to the C- I I acetate clearance constant k2, in
conjunction with measures of ventdcular work, allowed
determination of myocardial efficiency .
Despite an increase in myocardial oxygen consumption,
dobutamine led to increased myocardial efficiency . This
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finding and the significant reduction in systemic vascular
resistance and mitral regurgitation suggest that in this group
of patients, dobutamine has an important vasodilator action
in addition to its inotropic effect . The effect of dobutamine
on severity of mitral regurgitation is important when inter-
preting data assessing ventricular performance .
The measurement of myocardial oxygen consumption
from C- l I acetate PET and the estimation of efficiency could
potentially be utilized to complement existing clinical mea-
sures of ventricular performance, which may improve our
ability to appropriately evaluate therapies such as the use of
dobutamine in patients with heart failure. Such measures of
metabolic performance may provide objective criteria for
drug therapy in these patients and may aid in optimizing
therapy based on cardiac efficiency . Longitudinal investiga-
tions in larger study groups are necessary to assess the
prognostic utility of metabolic performance measurements in
congestive heart failure .
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